Tepotinib vs standard care for MET-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has a specific change called MET exon 14 skipping mutation, found through a biopsy or blood test.
- You must have had at least one prior cancer treatment (chemo or immunotherapy), but no more than two total prior treatments.
- You can be active or need some help with daily activities (ECOG status 0, 1, 2, or 3).
- You must have adequate kidney, liver, and blood cell counts as shown by routine lab tests.
- You have not been treated before with a drug that targets MET (like crizotinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Hear when a new MET Exon 14 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.